Preclinical safety, pharmacokinetics, pharmacodynamics, and biodistribution studies with Ad35K++ protein: a novel rituximab cotherapeutic

Rituximab is a mouse/human chimeric monoclonal antibody targeted toward CD20. It is efficient as first-line therapy of CD20-positive B-cell malignancies. However, a large fraction of treated patients relapse with rituximab-resistant disease. So far, only modest progress has been made in treatment op...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Mol Ther Methods Clin Dev
Hlavní autoři: Richter, Maximilian, Yumul, Roma, Saydaminova, Kamola, Wang, Hongjie, Gough, Michael, Baldessari, Audrey, Cattaneo, Roberto, Lee, Frank, Wang, Chung-Huei Katherine, Jang, Haishan, Astier, Anne, Gopal, Ajay, Carter, Darrick, Lieber, André
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2016
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4813608/
https://ncbi.nlm.nih.gov/pubmed/27069950
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/mtm.2016.13
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky